Theriva Biologics
TOVX
46 hedge funds and large institutions have $7.28M invested in Theriva Biologics in 2018 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 7 closing their positions.
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
0% less ownership
Funds ownership: 0% → 0% (-0%)
4% less funds holding
Funds holding: 48 → 46 (-2)
25% less capital invested
Capital invested by funds: $9.73M → $7.28M (-$2.45M)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
+$62K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$29.8K |
| 3 |
Invesco
Atlanta,
Georgia
|
+$9.18K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$9.18K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$4.59K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$71.2K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$31K |
| 3 |
SLG
Stanley-Laman Group
Berwyn,
Pennsylvania
|
-$19K |
| 4 |
SFSIG
San Francisco Sentry Investment Group
San Francisco,
California
|
-$17K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$13.8K |
TOVX Hedge Fund Activity: Q2 2018 in Review
46 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q2 2018, worth a combined $7.28M — down 25% from $9.73M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of TOVX and 5 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 9 added.
The largest buyer was William Blair & Company, adding an estimated $62K. The largest seller was Millennium Management, cutting an estimated $71.2K.
- 46 institutional investors held Theriva Biologics (TOVX) as of Q2 2018, down from 48 in Q1 2018.
- Funds reported $7.28M of Theriva Biologics stock for Q2 2018, down 25% quarter-over-quarter.
- 5 funds opened new Theriva Biologics positions in Q2 2018 and 7 closed out, a net change of -2 holders.
- The largest Theriva Biologics buyer in Q2 2018 was William Blair & Company, an estimated $62K added.
- The largest Theriva Biologics seller in Q2 2018 was Millennium Management, an estimated $71.2K sold.
Based on aggregated 13F filings for Q2 2018.